Forbes -- Abbott Laboratories reported on Tuesday that it has raised the bar for drug-coated stents and that competitor Boston Scientific is coming up short. The results of Abbott Laboratories (nyse: ABT - news - people )'s Spirit III trial comparing its Xience V stent with Boston Scientifics Taxus stent showed that Xience V is clinically superior.
